Date: 2015-05-05
Type of information: IPO
Company: Blueprint Medicines (USA - MA)
Investors:
Amount: $168.6 million
Funding type: IPO
Planned used:
Others: * On May 5, 2015, Blueprint Medicines announced the closing of its initial public offering of 9,367,708 shares of common stock at a public offering price of $18.00 per share, including shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the initial public offering to Blueprint Medicines were approximately $168.6 million, before underwriting discounts and estimated offering expenses. * On April 29, 2015, Blueprint Medicines announced the pricing of its initial public offering of 8,145,834 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. In addition, Blueprint Medicines granted the underwriters a 30-day option to purchase up to an additional 1,221,874 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on April 30, 2015 under the ticker symbol \"BPMC.\" * On March 24, 2015, Blueprint Medicines announced it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Blueprint Medicines intends to list its common stock under the symbol \"BPMC\" on The NASDAQ Global Market. Goldman, Sachs & Co. and Cowen and Company, LLC will act as joint book-running managers for the offering. JMP Securities will serve as a co-manager for the offering. Wedbush PacGrow will also serve as a co-manager for the offering.
Therapeutic area: Cancer - Oncology - Genetic diseases
